非布索坦2020价格

(Febuxostat) What is the price in 2020? Febuxostat (Febuxostat) is a xanthine oxidase (XO) inhibitor indicated for the long-term treatment of hyperuricemia with gout symptoms. Currently, there are three commonly used gout uric acid-lowering drugs in clinical practice: allopurinol, benzbromarone and febuxostat. Among them, febuxostat (febuxostat) has the strongest uric acid-lowering effect and has relatively fewer side effects. Febuxostat (Febuxostat) is a drug approved in 2009 for the treatment of chronic hyperuricemia. Compared with the traditional treatment drug allopurinol, febuxostat (febuxostat) is more effective in reducing uric acid. The most common adverse reactions are abnormal liver function, diarrhea and rash. Medication guidelines recommend a starting dose of 40 mg/d. In patients with mild to moderate renal impairment (creatinine clearance [CrCl] 30-89 mL/min), the starting dose is the same as in patients with normal renal function.

The price of Febuxostat (Febuxostat), the original drug in Japan, is higher than that in India, about $1,500 per box. Febuxostat (Febuxostat) produced by Zydus Pharmaceutical Factory in India has the same efficacy as the original drug, but the price is indeed much lower. The specification is 80mg*30 tablets/box. Its price is about 200$. Due to the floating exchange rate, the price cannot be accurate. For specific prices, please consult the regular overseas medical service company Medical Travel.

Among drugs that inhibit uric acid production, colchicine is mainly used in the acute phase (acute phase). Compared with febuxostat, it is mainly allopurinol. Compared with allopurinol, febuxostat (febuxostat) has the following advantages in addition to less side effects: 1. Allopurinol only inhibits reduced XOR, while febuxostat has a significant inhibitory effect on both oxidized and reduced XOR, so its uric acid-lowering effect is more powerful and long-lasting; 2. Since allopurinol is a purine analog, it will inevitably affect the activities of other enzymes involved in purine and pyridine metabolism. Therefore, repeated high-dose administration is required to maintain high drug levels during allopurinol treatment. This also leads to serious or even fatal adverse reactions due to drug accumulation. (Febuxostat) is a non-purine XOR inhibitor and therefore has a better safety profile.

Related hot article recommendations: